Ingene's TheraMAb technology
Executive Summary
NeoRx will have exclusive worldwide rights to products resulting from a cooperative R&D agreement with Ingene, and not worldwide rights to the TheraMAb technology as reported by "The Pink Sheet" (May 2, T&G-3). The agreement is royalty bearing on a product basis, and Ingene retains all rights to its technology.
NeoRx will have exclusive worldwide rights to products
resulting from a cooperative R&D agreement with Ingene, and not
worldwide rights to the TheraMAb technology as reported by "The
Pink Sheet" (May 2, T&G-3). The agreement is royalty bearing on
a product basis, and Ingene retains all rights to its
technology. |